These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17187516)

  • 1. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders.
    Turturro F
    Expert Rev Anticancer Ther; 2007 Jan; 7(1):11-7. PubMed ID: 17187516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denileukin diftitox: a concise clinical review.
    Eklund JW; Kuzel TM
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):33-8. PubMed ID: 15757436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing denileukin diftitox (Ontak) therapy.
    Duvic M; Talpur R
    Future Oncol; 2008 Aug; 4(4):457-69. PubMed ID: 18684057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with denileukin diftitox (ONTAK).
    Foss F
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S11-6. PubMed ID: 16516670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denileukin diftitox: a novel immunotoxin.
    Manoukian G; Hagemeister F
    Expert Opin Biol Ther; 2009 Nov; 9(11):1445-51. PubMed ID: 19817678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model.
    Knueppel A; Lange S; Altmann S; Sekora A; Knuebel G; Vogel H; Lindner I; Freund M; Junghanss C
    Vet Immunol Immunopathol; 2012 Jan; 145(1-2):233-40. PubMed ID: 22173275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denileukin diftitox as novel targeted therapy for lymphoid malignancies.
    Wong BY; Gregory SA; Dang NH
    Cancer Invest; 2007 Sep; 25(6):495-501. PubMed ID: 17882663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell lymphoma is associated with prolonged remission.
    Wong BY; Ma Y; Fitzwilson R; Dang NH
    Am J Hematol; 2008 Jul; 83(7):596-8. PubMed ID: 18383317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
    Foss FM
    Clin Lymphoma; 2000 Sep; 1(2):110-6; discussion 117. PubMed ID: 11707818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
    Dang NH; Hagemeister FB; Pro B; McLaughlin P; Romaguera JE; Jones D; Samuels B; Samaniego F; Younes A; Wang M; Goy A; Rodriguez MA; Walker PL; Arredondo Y; Tong AT; Fayad L
    J Clin Oncol; 2004 Oct; 22(20):4095-102. PubMed ID: 15353540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
    Dang NH; Pro B; Hagemeister FB; Samaniego F; Jones D; Samuels BI; Rodriguez MA; Goy A; Romaguera JE; McLaughlin P; Tong AT; Turturro F; Walker PL; Fayad L
    Br J Haematol; 2007 Feb; 136(3):439-47. PubMed ID: 17233846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma.
    Walker PL; Dang NH
    Clin J Oncol Nurs; 2004 Apr; 8(2):169-74. PubMed ID: 15108419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapies for chronic lymphocytic leukemia.
    Mavromatis BH; Cheson BD
    Blood Rev; 2004 Jun; 18(2):137-48. PubMed ID: 15010151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia.
    Frankel AE; Surendranathan A; Black JH; White A; Ganjoo K; Cripe LD
    Cancer; 2006 May; 106(10):2158-64. PubMed ID: 16586495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
    Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
    J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denileukin diftitox.
    Figgitt DP; Lamb HM; Goa KL
    Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.
    LeMaistre CF
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S37-40. PubMed ID: 11707862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression.
    Morgan SJ; Seymour JF; Prince HM; Westerman DA; Wolf MM
    Clin Cancer Res; 2004 May; 10(10):3572-5. PubMed ID: 15161717
    [No Abstract]   [Full Text] [Related]  

  • 19. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
    Frankel AE; Fleming DR; Hall PD; Powell BL; Black JH; Leftwich C; Gartenhaus R
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3555-61. PubMed ID: 14506141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
    Chin KM; Foss FM
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.